Cardiac Manifestations in COVID‐19 Patients-Admitted in Tertiary Care Hospital of Peshawar


  •   Muhammad Ali

  •   Hafsa Liaqat

  •   Saba Humayun

  •   Aisha Liaqat

  •   Javeria Liaqat

  •   Abdur Rauf


Objectives: To find the frequency of CVS diseases in admitted COVID patients and its associations with outcomes.

Methodology: A cross-sectional survey was conducted at tertiary care hospitals of Peshawar from April- June 2021. All patients admitted in COVID ward and COVID ICU, consenting to participate were included. Questionnaire along with patients ECG and Echo report, Canadian classification used for angina grading and NYHA classification to classify shortness of breath.

Results: The mean age of the sample (n=75) was 60.44 years. Majority were 44(58.66%) males and from ward 82.66%. According to responses using Canadian classification for chest pain were 61 (81.36%) class 2 angina, IN NYHA classification majority (72%) of patients had class 2 SOB. About 14.6% of patients echo showed positive ECHO findings. The average stay of patients were 7.45+-1.3 days .About 22.6% of mortality was noted, majority of expiry were from COVID icu (52.9%) and 69.3% of patients were discharged. About 21.33% of COVID patients had cardiac manifestations, majority were males 87.5%. 43.75% of mortality was seen in patients developing cardiac manifestations. 75% of patients that developed cardiac manifestation had multiple comorbidities, AF was reported in patients age 70 and above. NSTEMI was reported in patients with multiple comorbidities. Most of the Cardiac patients 78.66% did not have cardiac manifestations, only 16.9% of mortality was seen in patients with no cardiac manifestations.

Conclusion: Males are more prone to COVID and have more cardiac events. Age above 60 years develop more serious disease and adverse outcomes.

Keywords: COVID 19, CVS manifestations, health, patients


Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069.

Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4): 635-64.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497‐506.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-422.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020; 5: 811-818.

Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med. 2004; 351: 2611‐2618.

Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID‐19 and Multiorgan Response. Current Problems in Cardiology. 2020; 45(8): 100618.

Madjid M, Miller CC, Zarubaev VV, Marinich IG, Kiselev OI, Lobzin YV, et al. Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy‐confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects. Eur Heart J. 2007; 28: 1205‐1210.

He XW, Lai JS, Cheng J, Wang MW, Liu YJ, Xiao ZC, et al. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing ZaZhi. 2020; 48: E011-E011.

Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020; 17: 259-260.

Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020; 45: 230-232.

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8: 420-422.

Wang L, He WB, Yu XM, Liu HF, Zhou WJ, Jiang H. Prognostic value of myocardial injury in patients with COVID-19. Zhonghua Yan KeZaZhi. 2020; 56: E009-E009.

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020; 5(7): 802-810.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054-1062.

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al.Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virus pneumonia in Wuhan, China: a descriptive study. Lancet. 395(10223): 507-513.

Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020.

Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020; 133: 1025‐31.

Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST‐segment elevation in patients with Covid‐19—a case series. N Engl J Med. 2020; 382(25): 2478–2480.

Hua A, O'Gallagher K, Sado D, Byrne J. Life‐threatening cardiac tamponade complicating myo‐pericarditis in COVID‐19. Eur Heart J. 2020.

Asif T, Ali Z. Transient ST segment elevation in two patients with COVID‐19 and a normal transthoracic echocardiogram. Eur J Case Rep Intern Med. 2020; 7: 001672.

Zheng YY, Ma YT, Zhang JY, Xie X. COVID‐19 and the cardiovascular system. Nat Review Cardiol. 2020; 17: 259‐260.

Yoganathan A, Sajjad MS, Harky A. Cardiovascular disease and the impact of COVID‐19. J Card Surg. 2020.

Peng Peng X, Rong Hua T, Song L, Zi Yue Z, Bin F, Xi Ming W, et al. Risk factors for adverse clinical outcomes with COVID-19 in China: a multicenter, retrospective, observational study. Theranostics. 2020; 10(14): 6372–6383.

Du RH, Liang LR, Yang CQ, Wang W, Cao TZ, Li M, et al. Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2: A Prospective Cohort Study. Eur Respir J. 2020.

Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146(1): 110-118.

Jaillon S, Berthenet K, Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019; 56: 308–321.


Download data is not yet available.


How to Cite
Ali, M., Liaqat, H. ., Humayun, S., Liaqat, A., Liaqat, J., & Rauf, A. (2022). Cardiac Manifestations in COVID‐19 Patients-Admitted in Tertiary Care Hospital of Peshawar. European Journal of Medical and Health Sciences, 4(3), 27–33.